research Use of Glucagon-Like Peptide-1 (GLP-1) Agonists in Modulating Preexisting Dermatologic Disease: A Systematic Review
GLP-1 agonists may help treat certain skin conditions.
Search
for
Sort by
Research
30 / 399 results 
research GLP‐1 agonists and hair loss: a call for further investigation
More research is needed to understand if GLP-1 agonists affect hair health.
research GLP-1 Receptor Agonists: Beyond Their Pancreatic Effects
GLP-1 receptor agonists, like Dulaglutide, Liraglutide, and Semaglutide, have potential benefits beyond the pancreas, including neuroprotection, pain suppression, cardiovascular protection, obesity management, and cancer treatment, but there are concerns about pancreatitis and pancreatic cancer risks.
research Benefit-Risk Assessment of GLP-1 Receptor Agonists: Implications for Dermatologists and Plastic Surgeons
GLP-1 RAs help with diabetes and skin issues but can cause skin reactions and surgery challenges.
research The Impact of GLP-1 Receptor Agonists on Hair: Beneficial Effects or Adverse Outcomes?
GLP-1 receptor agonists may help or harm hair health, needing more research.
research Hair Loss Associated With Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist Use: A Systematic Review
GLP-1 receptor agonists may cause hair loss, but more research is needed.
research The Impact of GLP-1 Receptor Agonists on Hair: Beneficial Effects or Adverse Outcomes?
Glucagon-like peptide-1 receptor agonists (GLP-1RAs), used for type II diabetes and obesity, have shown mixed effects on hair conditions. While some studies report hair regrowth in androgenetic alopecia and reduced inflammation in cicatricial alopecia, others associate GLP-1RAs with telogen effluvium. Due to varied findings, careful clinical evaluation and monitoring are advised. Further controlled studies are needed to understand GLP-1RAs' impact on hair biology and ensure safe use without discontinuing beneficial treatments.
research Associations Between GLP‐1 Receptor Agonists and Alopecia: A Multi‐Centre Retrospective Analysis and Public Interest Trends
GLP-1 receptor agonists may increase the risk of a specific type of hair loss called androgenetic alopecia.
research Alopecia as an Emerging Adverse Effect Associated With Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists for Weight Loss: A Scoping Review
GLP-1 receptor agonists for weight loss may cause hair loss, especially in women.
research Dermatologic Implications of GLP-1 Receptor Agonist Medications: A Comprehensive Review
GLP-1 receptor agonists can cause skin reactions, facial fat loss, and hair loss, but may help with wound healing and skin conditions.
research Prevalence and Predictors of Hair Shedding among GLP-1 Receptor Agonist Users: A Cross-Sectional Study from Saudi Arabia
Hair shedding is common in GLP-1 users, affecting treatment adherence.
research Increased risk of hair loss with GLP-1 receptor agonists: A real-world multicenter TrinetX cohort study
research A Systematic Review of the Cutaneous Adverse Effects of GLP-1 Agonists
research Risk of Alopecia Areata with Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss
GLP-1 agonists may increase the risk of hair loss.
research The Role of Glucagon-Like Peptide-1 Receptor Agonists in Hair Loss: Clinical Evidence and Proposed Mechanisms
GLP-1RAs may cause hair loss but could also help regrow hair in some cases.
research Increased Incidence and Risk of Hair Loss with Glucagon-like Peptide 1 Receptor Agonists: A Real-World Multicentre Cohort Study
GLP-1RA therapy may increase the risk of hair loss.
research GLP-1 RAs and Skin Health: Exploring Dermatologic Side Effects and Therapeutic Interventions
GLP-1 receptor agonists can cause skin and hair issues due to rapid weight loss, but these can be managed with proper care and treatments.
research Exploring the hair loss risk in glucagon‐like peptide‐1 agonists: Emerging concerns and clinical implications
Newer GLP-1 drugs like semaglutide may cause hair loss.
research Clinical Effects of Glucagon-Like Peptide-1 Agonist Use for Weight Loss in Women With Polycystic Ovary Syndrome: A Scoping Review
GLP-1 receptor agonists help women with PCOS lose weight and improve health, but more research is needed on long-term effects.
research Effects of GLP ‐1 Receptor Agonists on Hair Loss and Regrowth: A Systematic Review
GLP-1 receptor agonists may cause hair loss, but regrowth is rare.
research “From evidence to practice” – Insights from the multidisciplinary team on the optimal integration of GLP ‐1 receptor agonists in obesity management services
GLP-1 receptor agonists help with weight loss but need to be combined with other treatments for best results.
research Effects of Glucagon-like Peptide-1 Receptor Agonists on Skin Homeostasis and Skin Aging Processes
GLP-1 RAs may help wound healing but can also cause faster facial aging and skin issues.
research GLP-1 therapies and hair loss: A systematic review of current evidence and implications for counseling
GLP-1 therapies, especially semaglutide and tirzepatide, may cause hair loss, particularly in women and with rapid weight loss.
research Glucagon-like peptide-1 receptor and proglucagon expression in mouse skin
Mice skin has components that could help with hair growth and might be used for diabetes treatment.
research Abstract 4142154: Risk of Suicide, Hair Loss, and Aspiration with Glucagon-like Peptide 1 Receptor Agonists: A Real-World Pharmacovigilance Study from the FAERS database
GLP1-RAs may have higher reports of suicide and hair loss, but no strong evidence links them to these issues.
research Hair Loss in Patients on Glucagon-Like Peptide 1 Receptor Agonists: Understanding Risks and Managing Outcomes
Glucagon-like peptide 1 receptor agonists (GLP-1RAs), used for type 2 diabetes and weight loss, have been linked to hair loss, particularly with semaglutide and tirzepatide, though causality is not established. Evidence primarily comes from pharmacovigilance databases and retrospective studies, with no prospective, controlled studies specifically addressing this issue. Rapid weight loss from these drugs may cause telogen effluvium, a potential mechanism for hair loss. As prescriptions rise in Europe, cases may increase, necessitating further research into causality and risk factors. Clinicians should inform and monitor patients for potential hair loss.
research The Impact of Glucagon-like Peptide-1 Receptor Agonists on Erectile Function: Friend or Foe?
The effect of GLP-1 RAs on erectile function is unclear and needs more research.
research Treatment of insulin resistance with tirzepatide leading to improvement of hair loss
Tirzepatide may improve hair loss by reducing insulin resistance.
research Non-Hormonal Treatment Options for Regulation of Menstrual Cycle in Adolescents with PCOS
Medications for glucose metabolism and weight control, combined therapy options, and herbal medicines may help regulate menstrual cycle in adolescents with PCOS.
research A Review of Metabolic Dysregulation in Lymphocytic Cicatricial Alopecia: Exploring the Connections and Therapeutic Implications
Metabolic issues may trigger lymphocytic cicatricial alopecia, and treatments targeting these issues could help.